Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.
NCT ID: NCT07117058
Last Updated: 2025-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
545 participants
OBSERVATIONAL
2025-03-18
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Mood Disorders Screening Scales in Geriatric Oncology
NCT02799524
Trajectories of Anxiety and Depression in Cancer Patients, Risk and Predictive Factors and Supportive Care; Prognostic Awareness and Shared Decision Making.
NCT07168096
Cultivating Resilience in Oncology Practice
NCT04902313
Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors
NCT06732375
Stepped-Care Telehealth for Distress in Cancer Survivors
NCT03060096
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
7-10 years old group
Develop and validate, using a psychometric method, a rapid screening tool for anxiety-depressive disorders in children cured of childhood cancer.
New rapid screening tool for anxiety and depressive disorders
New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)
Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
11-14 years old group
Develop and validate, using a psychometric method, a rapid screening tool for anxiety-depressive disorders in adolescents cured of childhood cancer.
New rapid screening tool for anxiety and depressive disorders
New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)
Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
15-25 years old group
Develop and validate, using a psychometric method, a rapid screening tool for anxiety-depressive disorders in young adults cured of childhood cancer.
New rapid screening tool for anxiety and depressive disorders
New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
HADS (Hospital Anxiety and Depression Scale)
Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
New rapid screening tool for anxiety and depressive disorders
New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)
Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
HADS (Hospital Anxiety and Depression Scale)
Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient whose intensive treatment had ended at least 3 months prior to inclusion,
* Patients considered to be in complete remission by the doctor responsible for their treatment,
* Patient affiliated to or entitled under a social security scheme,
* Patient having received informed information about the study OR the holder(s) of parental authority having received informed information about the study in the case of minors.
Exclusion Criteria
* Patients whose cancer has relapsed or progressed,
* Pregnant women, women in labor, breast-feeding mothers,
* Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than those of the research,
* Adults under legal protection (guardianship) or unable to express their consent.
7 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CLAIRE BERGER, MD
Role: PRINCIPAL_INVESTIGATOR
CHU SAINT-ETIENNE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire
Grenoble, , France
IHOP
Lyon, , France
Centre Hospitalier Universitaire
Rouen, , France
CHU de Saint-Etienne
Saint-Etienne, , France
Centre Hospitalier Universitaire
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A02404-43
Identifier Type: OTHER
Identifier Source: secondary_id
23CH131
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.